Authoritative Natural Medicine CRO & CDMO Whitepaper

OEM Safety And Efficacy Supplier & Suppliers

Transforming complex botanical active molecules into verified, reproducible, and regulatory-approved therapeutic deliverables across preclinical to commercial ecosystems.

Integrated Service Portfolio (Tier 1)

Primary OEM Safety & Efficacy Research Offerings

Standardized, audit-ready natural medicine contract solutions engineered to comply with ICH, FDA, and global pharmacopoeial monographs.

ODM Study and evaluation of the potency of the botanical active ingredient(s)

ODM Study and evaluation of the potency of the botanical active ingredient(s) from different seasons and different origins. Manufacturer, Suppliers

Explore Origin Matrix
14+
Years Specialized Natural Medicine R&D
300+
Full-Time Senior Research Scientists
83
Classic TCM Formulas Modernized
~400
Single-Herb Validated Quality Monographs
Industry Whitepaper Analysis

The Paradigm Shift in OEM Safety and Efficacy Sourcing

Global nutraceutical, pharmaceutical, and cosmeceutical developers are abandoning traditional commoditized sourcing in favor of verified analytical substantiation and translational validation.

From Empirical Use to Mechanistic Substantiation

For decades, natural medicines and herbal formulations were procured based on historical precedent or crude macroscopic appearance. Today, multinational brand owners face stringent regulatory mandates from the US FDA (21 CFR Part 111 & Part 312), the European Medicines Agency (EMA/HMPC), and the NMPA. The imperative has transitioned: suppliers must provide full chemical characterization, defined pathways of action (MOA), and rigorous toxicology profiles before an ingredient can enter commercial pipelines.

Mitigating Chromatographic & Bioactive Variance

Plant matrices fluctuate due to geographic elevation, soil microbiomes, climate variations, and harvest cycles. As a specialized natural medicine CRO & CDMO, MedGence (Yineng Pharma) eliminates raw-material instability. By evaluating botanical potency across seasons and territories, we establish definitive fingerprints via HPTLC, HPLC, and GC to guarantee batch-to-batch chemical equivalence and bioequivalence.

The CRO-to-CDMO Translational Advantage

A classic bottleneck in botanical product engineering is the failure of benchtop safety and efficacy trials to scale into commercial output. Contract researchers often produce unstable extracts that deteriorate in large-scale extraction or spray drying. MedGence integrates laboratory R&D directly with dedicated pilot facilities and managed commercial plants, protecting client IP and ensuring seamless tech transfer without quality loss.

Procurement Dynamics

Global Enterprise Procurement Requirements & Strategic Solutions

Navigating complex international supply landscapes demands holistic, audit-proof CRO/CDMO integrations.

Traceability & Origin Control

Procurement teams require comprehensive botanical provenance. Our database spanning hundreds of thousands of research batches connects geo-climatic harvest records directly to secondary metabolite concentration metrics.

Toxicological Safety Assurance

Complete preclinical toxicity dossiers: LD50 determination, acute 28-day toxicity, 90-day subchronic toxicity, Ames testing, in vitro mammalian chromosomal aberration, and in vivo micronucleus screening.

Translational Scalability (OEM/CDMO)

Seamless transition from gram-scale isolation to multi-ton GMP extraction. Custom finished delivery formats include concentrated liquid formulations, micro-encapsulated powders, softgels, functional tablets, and granules.

Stringent IP & Formula Protection

Strict non-disclosure agreements, segregated research networks, and dedicated batch suites ensure proprietary compound identities and processing temperatures remain fully shielded intellectual property.

Full-Stack Capabilities

12 Modular Natural Medicine R&D & CDMO Solutions

Clients can onboard MedGence for individual preclinical protocols or commission an end-to-end turnkey drug or dietary development contract.

1. Botanical Active Ingredient Screening

High-throughput identification of plant secondary metabolites (alkaloids, flavonoids, polysaccharides, saponins). We isolate candidates with target bioactivity while screening out cytotoxic analogs.

2. Potency Evaluation by Origin & Season

Systematic quantification of active fraction densities according to agro-ecological zones and developmental harvest stages, locking in raw material specifications that maximize industrial yield.

3. Analytical Method Establishment

Development and ICH Q2(R1) validation of assay methodologies: HPLC, HPTLC, GC, LC-MS/MS, and high-resolution fingerprinting to secure batch-to-batch chemical conformity.

4. Manufacturing Process Study for Actives

Optimization of critical process parameters (CPPs): pretreatment milling, dynamic counter-current extraction, macroporous resin adsorption, nanofiltration, and lyophilization.

5. Process Study for Finished Products

Overcoming bio-absorption limitations, poor dissolution, hygroscopicity, and thermal degradation during compression, softgel encapsulation, or aseptic liquid bottling.

6. Toxicity & Preclinical Safety Studies

Comprehensive GLP-compliant toxicological screening: oral LD50, acute system toxicity, genotoxicity (Ames, Micronucleus), and repeat-dose chronic toxicity assessments.

7. In Vitro Testing & Mechanistic Assays

Cellular and enzymatic pathway evaluations: anti-inflammatory cytokine assays (TNF-α, IL-6), antioxidant capacity (ORAC, DPPH), metabolic regulation, and antiviral target inhibition.

8. In Vivo Animal Pharmacodynamics

Validated disease models in rodents to substantiate target therapeutic claims for metabolic syndrome, neuroprotection, immune modulation, and cardiovascular recovery.

9. Clinical Studies (Phase I – IV)

Human trials executed under GCP guidelines: small-cohort dietary supplement efficacy trials and multi-center Phase I through Phase IV studies supporting full New Drug Applications (NDA).

10. Natural Formulation Research

Translating classic TCM polyherbal compatibility theories (Jun-Chen-Zuo-Shi) into modern synergized compositions with enhanced bioavailability and reduced competitive antagonism.

11. Contract Manufacturing (OEM) for Actives

Industrial supply of standardized botanical APIs and functional intermediates: concentrated bio-extracts, spray-dried uniform powders, standardized pastes, and supercritical fluid volatile oils.

12. Turnkey Finished Dosage CDMO

Commercial-scale packaging and processing under strict cGMP environments: oral liquid vials, vegetable hard capsules, enteric softgels, precision-scored tablets, and sachets.

Compliance Assurance

Localized Compliance & Global Regulatory Defensibility

Bridging Chinese pharmacopoeial production assets with rigorous transatlantic and Asia-Pacific statutory frameworks.

North American Compliance (FDA / NDI / GRAS)

Every active botanical ingredient developed for North America is harmonized with FDA Dietary Supplement Health and Education Act (DSHEA) parameters. We furnish exhaustive New Dietary Ingredient (NDI) notifications, self-affirmed Generally Recognized as Safe (GRAS) expert dossiers, pesticide residue limits conforming to USP <561>, and heavy metal quantifications adhering to California Proposition 65 thresholds.

European Union Directives (EFSA / Novel Food)

Navigating the EU regulatory framework requires rigorous proof of non-novel history or comprehensive Novel Food Applications under Regulation (EU) 2015/2283. Our laboratories generate chromatographic polycyclic aromatic hydrocarbon (PAH) profiles, mycotoxin screens, and ethylene oxide (ETO) absence certificates to ensure seamless customs clearance across all EU member states.

Chinese Domestic Registrations (NMPA & Hospital Preparations)

With 56 hospital preparation approvals and 22 innovative natural drug pipelines completed, MedGence provides unparalleled navigation through China's National Medical Products Administration (NMPA) Class 1, 2, and 3 botanical licensing, transforming classic formulas into registered, commercially defensible entities.

Innovation Trajectory

Technology Roadmap: Next-Generation Botanical AI & Synthesis

Where ancient ethnobotanical wisdom converges with modern computational pharmacology and green processing technologies.

Phase 1: In Vitro Omics

AI-Assisted Target Deconvolution

Integrating network pharmacology and molecular docking simulations to predict multi-target interactions of botanical compounds across specific cellular receptors before wet-lab synthesis begins.

Phase 2: Green Extraction

Continuous Deep Eutectic Extraction

Deploying natural deep eutectic solvents (NADES) combined with ultrasound and supercritical CO2 to eliminate toxic petroleum solvents, yielding pristine bioactives with minimal environmental footprint.

Phase 3: Delivery Systems

Nano-Phytosome Microencapsulation

Engineering lipid-based phytosomal delivery vehicles to solve the native bioavailability constraints of polyphenols and terpenoids, increasing oral absorption by up to 400% in human trials.

Phase 4: Commercial Scale

Closed-Loop PAT Manufacturing

Embedding Process Analytical Technology (PAT) and near-infrared (NIR) sensors throughout commercial CDMO extractors for real-time potency tuning and predictive batch uniformity.

Proven Enterprise Collaborations

Trusted by Over 100 Leading Pharmaceutical Groups & Research Hospitals

Our validated natural medicine R&D ecosystem supports national drug manufacturing conglomerates, elite university clinics, and forward-thinking consumer brands.

China Beijing Tongrentang Group Tongrentang Group
China Resources Sanjiu CR Sanjiu
Sunflower Pharmaceutical Group Sunflower Pharma
Livzon Pharmaceutical Group Livzon Pharma
Dihon Pharmaceutical Group Dihon Pharma
Golden Throat Holdings Group Golden Throat
Yangtzi River Pharmaceutical Group Yangtzi River Pharma
Beihai Gofar Chuanshan Biological Beihai Gofar
Humanwell Healthcare Group Humanwell Healthcare
SCIMYTH Pharmaceutical Group SCIMYTH Pharma
Shandong Hanfang Pharmaceutical Shandong Hanfang
Luoxin Pharmaceutical Group Luoxin Pharma
Guangdong Zhongsheng Pharmaceutical Zhongsheng Pharma
Apeloa Pharmaceutical Apeloa Pharma
Hunan Heng Chang Pharmaceutical Heng Chang Pharma
Baotou Traditional Chinese Medicine Baotou TCM
Shuguang Hospital Affiliated to Shanghai University of TCM Shuguang Hospital
Second Xiangya Hospital of Central South University Second Xiangya Hospital
Procurement Knowledge Base

Frequently Asked Questions: OEM Safety & Efficacy

Clear, authoritative technical clarifications for supply chain leaders, chief scientific officers, and regulatory specialists.

What role does a natural medicine CRO/CDMO play in product development?
A specialized CRO like MedGence manages the entire lifecycle of botanical innovation: phytochemical screening, seasonal potency evaluations, chemical standard setting (HPTLC, HPLC), preclinical GLP toxicological assays, in vitro cell-based testing, in vivo animal disease efficacy verification, human clinical trials (Phase I-IV), through to full commercial-scale GMP contract manufacturing of active ingredients and finished delivery forms.
How does MedGence solve seasonal and geographical active ingredient batch variations?
We map secondary metabolite variations across diverse agro-climatic origins and seasonal windows. Using high-resolution chromatographic fingerprints, our team identifies the peak bioactive harvest time and sets quantitative standards. We then establish standardized extraction blending parameters to maintain tight batch-to-batch chemical specifications across every shipment.
What toxicological documentation is provided to support international regulatory filings?
We deliver complete GLP dossiers including acute oral LD50 determination, 28-day and 90-day subchronic toxicity data, and comprehensive genotoxicity batteries (Ames test, in vitro chromosomal aberration, in vivo micronucleus). These data packets directly support US FDA NDI notifications, European EFSA submissions, and Chinese NMPA botanical filings.
How is customer formulation IP protected across contract research and commercial manufacturing?
We operate under an entrusted contract model protected by enforceable international Non-Disclosure Agreements (NDAs). Research runs within segregated project suites, and process formulas and operational parameters remain customer-owned trade secrets that are never shared or commercialized without explicit client authorization.
Which finished dosage formats can be engineered and manufactured at scale?
Active compounds can be supplied as concentrated liquids, spray-dried micro-powders, paste extracts, or supercritical volatile oils. For finished consumer dosage forms, our CDMO facilities produce oral liquid ampoules, hard-shell capsules, vegetarian softgels, scored tablets, effervescent granules, and multi-ingredient sachets.
Can MedGence design human clinical trials for dietary supplements and drug candidates?
Yes. We structure both small-cohort randomized, double-blind, placebo-controlled human clinical trials for consumer efficacy substantiation, as well as formal GCP-compliant Phase I, Phase II, Phase III, and post-market Phase IV trials required for pharmaceutical botanicals and hospital preparation approvals.
Integrated Service Portfolio (Tier 2)

Commercial Verification & Pilot Specifications

Access our direct laboratory endpoints, specialized bioassay protocols, and commercial botanical CDMO contracts.

ODM Study and evaluation of the potency of the botanical active ingredient(s)

ODM Study and evaluation of the potency of the botanical active ingredient(s) from different seasons and different origins. Manufacturer, Suppliers

Download Potency Indices